PhoneEmailLinkedInYouTube
MFX Biotech2022-06-15T17:59:34+01:00

Want to talk?

Call us: 0 330 330 3503

Want to write?

Email Us

COVID-19 testing as accurate as PCR – but in 15 minutes

State of the art immunofluorescence technology means 240+ tests per hour on a single machine. CE-marked IVD for use EU-wide

EXCEEDS MHRA PERFORMANCE CHARACTERISTICS FOR POINT OF CARE TESTING

Find Out More About Performance

AFS-1000 Analyser

Immunofluorescence assay to process 240+ samples per hour.

Fast Time to Result

Reaction takes 15mins – then AFS-1000 gives result in under 10 seconds.

Exquisite Accuracy

Test for COVID-19 infection with Sensitivity, Specificity and Limit of Detection on a par with LAMP and PCR.

We provide cutting edge point-of care diagnostic technologies.

Platforms that can run multiple immunofluorescence chromatography assays – including for active COVID-19 infection and IgG / IgM. Fully CE-marked for use EU-wide.

100% Concordance with PCR

In independent clinical trials, the AFS-1000 with the COVID-19 cassette agreed 100% with all positive clinical samples to a Ct value of 39 on PCR.

Neutralising Antibody Test

Test now available for neutralising antibodies against the viral spike protein – the antibodies elicited by current vaccines.

Scale, Speed and Support

We’ve partnered with one of the world’s largest manufacturers of high-tech diagnostic reagents and instruments to give you cost-efficient, rapid, easy-to-operate diagnostics.

How do we measure accuracy?

Most manufacturers brag about sensitivity and specificity.

But that’s not the whole picture. Those are of little use if a test only identifies people with the highest levels of virus. 

0%
Sensitivity

Sensitivity is the ability of a test to correctly identify patients with a disease.

0%
Specificity

Specificity is the ability of a test to correctly identify patients without the disease.

0TCID50/ml
Limit of Detection

How much virus needs to be in the sample for a reliably positive result.

The MFX Biotech machine reader with our exclusive COVID-19 assay has a Limit of Detection of 0.5TCID50/ml or 0.02ng/ml of n-protein. That means it can detect viral levels down to 100 copies per ml – as low as many PCR and LAMP tests. For comparison, visually-read lateral flow devices need at least 200-300x more virus present to give a positive result.

Our test exceeds the highest standard for performance characteristics set by the MHRA.

Find Out More

News

A game-changing innovation in COVID-19 testing.

A game-changing innovation in COVID-19 testing.

Only diagnoses active infections: no false positives due to past infections – unlike PCR and LAMP

Meet the Team

A wealth of experience in supporting the medical industry backed up with scientific and logistical expertise.

Paul Matthews

Paul has more than twenty years’ experience in various commercial roles. His background includes senior positions in Forex, marketing, aviation, and business management.

Simon Lane

Simon has a wealth of board experience in an eclectic mix of industries from biotech to precious metals to FMCG. Simon leads the MFX client exerience team and relishes the complex challenges that COVID-19 testing presents.

Contact Us

Please get in touch and one of our team will be in contact. No pushy salesmen – promise – we just let the science do the talking.

0 330 330 3503

enquiries@mfxbiotech.com

450 Bath Rd | West Drayton UB6 0EB

This website uses cookies and third party services. OK
Go to Top